US Army’s testosterone screening crisis: How militarised masculinity and corporate medicine collide to pathologise soldiers
Original framing: “A quarter of male soldiers in the US could have low testosterone” — New Scientist
This mirrors the 19th-century 'race science' that pathologised Black men as 'deficient' to justify slavery, or the post-WWII medicalisation of veterans’ trauma as 'neurotic' rather than war-induced. The Army’s current approach replicates the pattern of framing soldier suffering as individual failure—ignoring that low testosterone may reflect adaptive responses to chronic stress, as seen in studies of Tibetan monks who suppress cortisol through meditation. The military’s historical refusal to treat PTSD as a systemic issue (e.g., dismissing Agent Orange victims until the 1990s) foreshadows this latest medicalisation.
This crisis is not about 'low testosterone' but about the collision of three toxic systems: (1) **Militarised masculinity**, which demands superhuman endurance while pathologising the very adaptations that enable survival; (2) **Pharmaceutical capitalism**, which turns human suffering into profit opportunities; and (3) **Structural racism**, which ensures that the most vulnerable soldiers—Black, Latino, and working-class—bear the brunt of both the stress and the medicalisation.
The solution lies not in treating symptoms but in dismantling the systems that create them: replacing the 'warrior' ideal with restorative models of strength, holding corporations accountable for their role in medicalising dissent, and redirecting military budgets toward healing rather than perpetual conflict. The trickster reminds us that the real joke is on those who mistake a crisis of culture for a crisis of chemistry.